Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2014

Open Access 01-03-2014 | Article

Heterogeneity among septic shock patients in a set of immunoregulatory markers

Authors: H. Janols, M. Wullt, C. Bergenfelz, S. Björnsson, H. Lickei, S. Janciauskiene, K. Leandersson, A. Bredberg

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2014

Login to get access

Abstract

Immune activation is a regular feature of sepsis, but the incidence and nature of the ensuing inflammation-resolving and immunosuppressive component is less well understood. In this study, we compared immunoregulatory markers on blood leukocytes from patients with Gram-negative or Gram-positive sepsis or septic shock, and compared this to blood from patients with severe virosis or healthy controls. To this end, blood from 32 patients with sepsis, including ten cases with shock, and 12 patients with severe virosis were analysed by flow cytometry for the expression levels of monocyte HLA-DR, CD11c, CD14 and CD40, and for frequencies of CD163+-suppressive monocytes, HLA-DR+ or CD40+-activated T cells and Tregs. Plasma cytokine levels were analysed as a functional measurement. Signs of immunosuppression dominated in the septic shock and Gram-positive sepsis groups, whereas monocyte activation was common in Gram-negative sepsis patients without shock. However, the main finding was the large inter-individual variation of immune activation and immunosuppression, with no correlation to prognosis among the shock patients. The pronounced inter-individual variation in the analysed monocyte and lymphocyte markers forms a strong argument that, when immunomodulatory treatment is considered in a sepsis patient, it should be personalised and guided by a detailed immune status assessment.
Literature
1.
go back to reference Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348(16):1546–1554PubMedCrossRef Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348(16):1546–1554PubMedCrossRef
2.
go back to reference Harrison DA, Welch CA, Eddleston JM (2006) The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 10(2):R42PubMedCrossRef Harrison DA, Welch CA, Eddleston JM (2006) The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 10(2):R42PubMedCrossRef
3.
go back to reference Melamed A, Sorvillo FJ (2009) The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Crit Care 13(1):R28PubMedCrossRef Melamed A, Sorvillo FJ (2009) The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Crit Care 13(1):R28PubMedCrossRef
4.
go back to reference Wiersinga WJ (2011) Current insights in sepsis: from pathogenesis to new treatment targets. Curr Opin Crit Care 17(5):480–486PubMedCrossRef Wiersinga WJ (2011) Current insights in sepsis: from pathogenesis to new treatment targets. Curr Opin Crit Care 17(5):480–486PubMedCrossRef
5.
go back to reference Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348(2):138–150PubMedCrossRef Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348(2):138–150PubMedCrossRef
6.
go back to reference Ulloa L, Tracey KJ (2005) The “cytokine profile”: a code for sepsis. Trends Mol Med 11(2):56–63PubMedCrossRef Ulloa L, Tracey KJ (2005) The “cytokine profile”: a code for sepsis. Trends Mol Med 11(2):56–63PubMedCrossRef
7.
go back to reference Hotchkiss RS, Opal S (2010) Immunotherapy for sepsis—a new approach against an ancient foe. N Engl J Med 363(1):87–89PubMedCrossRef Hotchkiss RS, Opal S (2010) Immunotherapy for sepsis—a new approach against an ancient foe. N Engl J Med 363(1):87–89PubMedCrossRef
8.
go back to reference Angus DC (2011) The search for effective therapy for sepsis: back to the drawing board? JAMA 306(23):2614–2615PubMedCrossRef Angus DC (2011) The search for effective therapy for sepsis: back to the drawing board? JAMA 306(23):2614–2615PubMedCrossRef
9.
go back to reference Wenzel RP, Edmond MB (2012) Septic shock—evaluating another failed treatment. N Engl J Med 366(22):2122–2124PubMedCrossRef Wenzel RP, Edmond MB (2012) Septic shock—evaluating another failed treatment. N Engl J Med 366(22):2122–2124PubMedCrossRef
10.
12.
go back to reference Sinistro A, Almerighi C, Ciaprini C, Natoli S, Sussarello E, Di Fino S et al (2008) Downregulation of CD40 ligand response in monocytes from sepsis patients. Clin Vaccine Immunol 15(12):1851–1858PubMedCentralPubMedCrossRef Sinistro A, Almerighi C, Ciaprini C, Natoli S, Sussarello E, Di Fino S et al (2008) Downregulation of CD40 ligand response in monocytes from sepsis patients. Clin Vaccine Immunol 15(12):1851–1858PubMedCentralPubMedCrossRef
13.
go back to reference Skrupky LP, Kerby PW, Hotchkiss RS (2011) Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology 115(6):1349–1362PubMedCentralPubMed Skrupky LP, Kerby PW, Hotchkiss RS (2011) Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology 115(6):1349–1362PubMedCentralPubMed
14.
go back to reference Huttunen R, Aittoniemi J (2011) New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis. J Infect 63(6):407–419PubMedCrossRef Huttunen R, Aittoniemi J (2011) New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis. J Infect 63(6):407–419PubMedCrossRef
15.
go back to reference Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM et al (1999) Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27(7):1230–1251PubMedCrossRef Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM et al (1999) Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27(7):1230–1251PubMedCrossRef
16.
go back to reference Schwulst SJ, Grayson MH, DiPasco PJ, Davis CG, Brahmbhatt TS, Ferguson TA et al (2006) Agonistic monoclonal antibody against CD40 receptor decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol 177(1):557–565PubMed Schwulst SJ, Grayson MH, DiPasco PJ, Davis CG, Brahmbhatt TS, Ferguson TA et al (2006) Agonistic monoclonal antibody against CD40 receptor decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol 177(1):557–565PubMed
17.
go back to reference Unsinger J, Kazama H, McDonough JS, Hotchkiss RS, Ferguson TA (2009) Differential lymphopenia-induced homeostatic proliferation for CD4+ and CD8+ T cells following septic injury. J Leukoc Biol 85(3):382–390PubMedCrossRef Unsinger J, Kazama H, McDonough JS, Hotchkiss RS, Ferguson TA (2009) Differential lymphopenia-induced homeostatic proliferation for CD4+ and CD8+ T cells following septic injury. J Leukoc Biol 85(3):382–390PubMedCrossRef
18.
go back to reference Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101(6):1644–1655PubMedCrossRef Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101(6):1644–1655PubMedCrossRef
19.
go back to reference Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S, Liebenberg V et al (2009) Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 69(2):599–608PubMedCrossRef Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S, Liebenberg V et al (2009) Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 69(2):599–608PubMedCrossRef
20.
go back to reference Bourgeois C, Rocha B, Tanchot C (2002) A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297(5589):2060–2063PubMedCrossRef Bourgeois C, Rocha B, Tanchot C (2002) A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297(5589):2060–2063PubMedCrossRef
21.
go back to reference Brunialti MK, Santos MC, Rigato O, Machado FR, Silva E, Salomao R (2012) Increased percentages of T helper cells producing IL-17 and monocytes expressing markers of alternative activation in patients with sepsis. PLoS One 7(5):e37393PubMedCrossRef Brunialti MK, Santos MC, Rigato O, Machado FR, Silva E, Salomao R (2012) Increased percentages of T helper cells producing IL-17 and monocytes expressing markers of alternative activation in patients with sepsis. PLoS One 7(5):e37393PubMedCrossRef
22.
go back to reference Janols H, Bredberg A, Thuvesson I, Janciauskiene S, Grip O, Wullt M (2010) Lymphocyte and monocyte flow cytometry immunophenotyping as a diagnostic tool in uncharacteristic inflammatory disorders. BMC Infect Dis 10:205PubMedCentralPubMedCrossRef Janols H, Bredberg A, Thuvesson I, Janciauskiene S, Grip O, Wullt M (2010) Lymphocyte and monocyte flow cytometry immunophenotyping as a diagnostic tool in uncharacteristic inflammatory disorders. BMC Infect Dis 10:205PubMedCentralPubMedCrossRef
24.
go back to reference Moore CS, Crocker SJ (2012) An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 180(1):12–16PubMedCrossRef Moore CS, Crocker SJ (2012) An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 180(1):12–16PubMedCrossRef
25.
go back to reference Barreiro LB, Tailleux L, Pai AA, Gicquel B, Marioni JC, Gilad Y (2012) Deciphering the genetic architecture of variation in the immune response to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 109(4):1204–1209PubMedCentralPubMedCrossRef Barreiro LB, Tailleux L, Pai AA, Gicquel B, Marioni JC, Gilad Y (2012) Deciphering the genetic architecture of variation in the immune response to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 109(4):1204–1209PubMedCentralPubMedCrossRef
26.
go back to reference Lin RY, Astiz ME, Saxon JC, Rackow EC (1993) Altered leukocyte immunophenotypes in septic shock. Studies of HLA-DR, CD11b, CD14, and IL-2R expression. Chest 104(3):847–853PubMedCrossRef Lin RY, Astiz ME, Saxon JC, Rackow EC (1993) Altered leukocyte immunophenotypes in septic shock. Studies of HLA-DR, CD11b, CD14, and IL-2R expression. Chest 104(3):847–853PubMedCrossRef
27.
go back to reference Xu PB, Lou JS, Ren Y, Miao CH, Deng XM (2012) Gene expression profiling reveals the defining features of monocytes from septic patients with compensatory anti-inflammatory response syndrome. J Infect 65(5):380–391PubMedCrossRef Xu PB, Lou JS, Ren Y, Miao CH, Deng XM (2012) Gene expression profiling reveals the defining features of monocytes from septic patients with compensatory anti-inflammatory response syndrome. J Infect 65(5):380–391PubMedCrossRef
28.
go back to reference Brunialti MK, Martins PS, Barbosa de Carvalho H, Machado FR, Barbosa LM, Salomao R (2006) TLR2, TLR4, CD14, CD11B, and CD11C expressions on monocytes surface and cytokine production in patients with sepsis, severe sepsis, and septic shock. Shock 25(4):351–357PubMedCrossRef Brunialti MK, Martins PS, Barbosa de Carvalho H, Machado FR, Barbosa LM, Salomao R (2006) TLR2, TLR4, CD14, CD11B, and CD11C expressions on monocytes surface and cytokine production in patients with sepsis, severe sepsis, and septic shock. Shock 25(4):351–357PubMedCrossRef
29.
go back to reference Biswas SK, Lopez-Collazo E (2009) Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 30(10):475–487, Research Support, Non-U.S. Gov’t ReviewPubMedCrossRef Biswas SK, Lopez-Collazo E (2009) Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 30(10):475–487, Research Support, Non-U.S. Gov’t ReviewPubMedCrossRef
30.
go back to reference Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29(7):1303–1310PubMedCrossRef Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29(7):1303–1310PubMedCrossRef
31.
go back to reference Opal SM, Girard TD, Ely EW (2005) The immunopathogenesis of sepsis in elderly patients. Clin Infect Dis 41(Suppl 7):S504–S512PubMedCrossRef Opal SM, Girard TD, Ely EW (2005) The immunopathogenesis of sepsis in elderly patients. Clin Infect Dis 41(Suppl 7):S504–S512PubMedCrossRef
32.
go back to reference Schröder J, Kahlke V, Staubach KH, Zabel P, Stüber F (1998) Gender differences in human sepsis. Arch Surg 133(11):1200–1205PubMedCrossRef Schröder J, Kahlke V, Staubach KH, Zabel P, Stüber F (1998) Gender differences in human sepsis. Arch Surg 133(11):1200–1205PubMedCrossRef
33.
go back to reference Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR et al (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405(6785):458–462PubMedCrossRef Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR et al (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405(6785):458–462PubMedCrossRef
34.
go back to reference Serhan CN (2007) Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25:101–137PubMedCrossRef Serhan CN (2007) Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25:101–137PubMedCrossRef
35.
go back to reference Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, Green JM (2012) A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care 16(3):R112PubMedCrossRef Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, Green JM (2012) A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care 16(3):R112PubMedCrossRef
36.
go back to reference Porta C, Riboldi E, Totaro MG, Strauss L, Sica A, Mantovani A (2011) Macrophages in cancer and infectious diseases: the ‘good’ and the ‘bad’. Immunotherapy 3(10):1185–1202PubMedCrossRef Porta C, Riboldi E, Totaro MG, Strauss L, Sica A, Mantovani A (2011) Macrophages in cancer and infectious diseases: the ‘good’ and the ‘bad’. Immunotherapy 3(10):1185–1202PubMedCrossRef
37.
go back to reference Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH et al (2011) Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306(23):2594–2605PubMedCentralPubMedCrossRef Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH et al (2011) Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306(23):2594–2605PubMedCentralPubMedCrossRef
38.
go back to reference Amlot PL, Tahami F, Chinn D, Rawlings E (1996) Activation antigen expression on human T cells. I. Analysis by two-colour flow cytometry of umbilical cord blood, adult blood and lymphoid tissue. Clin Exp Immunol 105(1):176–182PubMedCentralPubMedCrossRef Amlot PL, Tahami F, Chinn D, Rawlings E (1996) Activation antigen expression on human T cells. I. Analysis by two-colour flow cytometry of umbilical cord blood, adult blood and lymphoid tissue. Clin Exp Immunol 105(1):176–182PubMedCentralPubMedCrossRef
40.
go back to reference Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS (2010) Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 88(2):233–240PubMedCrossRef Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS (2010) Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 88(2):233–240PubMedCrossRef
41.
go back to reference Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J et al (2009) Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 180(7):640–648PubMedCrossRef Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J et al (2009) Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 180(7):640–648PubMedCrossRef
Metadata
Title
Heterogeneity among septic shock patients in a set of immunoregulatory markers
Authors
H. Janols
M. Wullt
C. Bergenfelz
S. Björnsson
H. Lickei
S. Janciauskiene
K. Leandersson
A. Bredberg
Publication date
01-03-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2014
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-013-1957-y

Other articles of this Issue 3/2014

European Journal of Clinical Microbiology & Infectious Diseases 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.